ESC 365 - Are there more NVAF patients that would benefit from anticoagulation with a NOAC?

Open Access

Are there more NVAF patients that would benefit from anticoagulation with a NOAC?

Session: Oral anticoagulation, thrombosis and bleeding – Improving patient care with NOACs

Topic: Atrial fibrillation (AF)

Speaker: Professor J. Healey (Hamilton, CA)

Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Jeff Healey

Population Health Research Institute, Hamilton (Canada)

18 presentations

1 follower

5 more presentations in this session

Improving patient care with NOACs – Where are we now?

Speaker: Professor F. Andreotti (Rome, IT)

Thrombosis versus bleeding risk in NVAF patients – From trials to clinical practice.

Speaker: Professor G. Lip (Liverpool, GB)

Oral anticoagulation – Managing challenging patients with NVAF.

Speaker: Professor H. Darius (Berlin, DE)

Can evidence from VTE treatment trials with NOACs inform the cardiologist?

Speaker: Doctor A. Cohen (London, GB)

Optimising patient care with NOACs – Panel discussion.

Speaker: Professor H. Darius (Berlin, DE) Professor F. Andreotti (Rome, IT)

Access the full session

Oral anticoagulation, thrombosis and bleeding – Improving patient care with NOACs

Speakers: Professor J. Healey, Professor F. Andreotti, Professor G. Lip, Professor H. Darius, Doctor A. Cohen...

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources